文献速递肿瘤 PET/CT

89Zr-girentuximab与18F-FDG PET/CT在新诊断转移性肾细胞癌中的病灶检测

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-06-06

该研究为IMPACT-RCC研究的初步分析,纳入42例新诊断、预后良好或中等、适合观察等待的转移性透明细胞肾细胞癌患者,比较基线增强CT、[89Zr]Zr-DFO-girentuximab-PET/CT与[18F]FDG-PET/CT的病灶检测能力;联合girentuximab-PET/CT与CT检测病灶比例高于单独CT(91% vs 56%,p=0.001),也高于CT联合FDG-PET/CT(84%,p<0.005)。

要点

  • 联合[89Zr]Zr-DFO-girentuximab-PET/CT与CT病灶检出率91%,高于单独CT的56%。
  • 联合girentuximab-PET/CT与CT检出率也高于CT联合[18F]FDG-PET/CT的84%。
  • 两种PET/CT较单独CT均检出更多骨和软组织病灶。

核心结论

  • 在新诊断、预后良好或中等、适合观察等待的mccRCC患者中,将[89Zr]Zr-DFO-girentuximab-PET/CT或[18F]FDG-PET/CT加入CT可较单独CT提高病灶检测。

研究设计与样本

  • IMPACT-RCC研究的初步分析,2015年2月至2018年3月纳入42例新诊断、预后良好或中等、适合观察等待的mccRCC患者。
  • 患者基线接受CT、[89Zr]Zr-DFO-girentuximab-PET/CT和[18F]FDG-PET/CT检查,扫描独立审阅,分析CT上≥10 mm病灶和≥15 mm淋巴结。

主要发现

  • 至少一种模态共检出449个病灶,中位每例7个(ICR 4.25-12.75),42%位于肺、22%位于淋巴结、10%位于骨。
  • 联合[89Zr]Zr-DFO-girentuximab-PET/CT与CT检出病灶91%(95%CI 87-94),高于单独CT的56%(95%CI 50-62,p=0.001)。
  • 联合[89Zr]Zr-DFO-girentuximab-PET/CT与CT检出病灶91%(95%CI 87-94),高于CT联合[18F]FDG-PET/CT的84%(95%CI 79-88,p<0.005)。
  • 两种PET/CT与单独CT相比均检出更多骨和软组织病灶。

关键数值与推荐

  • 视觉判断[89Zr]Zr-DFO-girentuximab或[18F]FDG摄取超过背景者测量SUVmax。
  • CT分析病灶标准为≥10 mm,淋巴结为≥15 mm。

临床怎么用

  • 对于新诊断、预后良好或中等、考虑观察等待的mccRCC患者,可考虑在CT基础上加做[89Zr]Zr-DFO-girentuximab-PET/CT以提高病灶检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model. METHODS: Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [89Zr]Zr-DFO-girentuximab or [18F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUVmax) were measured. RESULTS: A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25-12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87-94) versus 56% (95%CI: 50-62, p = 0.001), respectively, and more than CT and [18F]FDG-PET/CT combined (84% (95%CI:79-88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone. CONCLUSIONS: The addition of [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Verhoeff SR, van Es SC, Boon E, et al. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31172212. doi:10.1007/s00259-019-04358-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。